News|Articles|November 19, 2026

Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease

Author(s)Marco Meglio
Listen
0:00 / 0:00

Key Takeaways

  • SPINOZA randomizes ~400 preclinical AD participants to obicetrapib 10 mg vs placebo, stratified by APOE genotype, with optional 26-week open-label extension and prespecified interim sample-size re-estimation.
  • The primary endpoint is week-52 change in plasma p-tau217, supported by secondary endpoints spanning plasma Aβ42/40, tau-related measures, and PACC5 cognitive performance.
SHOW MORE

A new phase 2b trial, SPINOZA, will test whether obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, slows Alzheimer disease biomarker progression in APOE-stratified, cognitively unimpaired adults.

At the 2026 Clinical Trials on Alzheimer's Disease (CTAD) meeting, held November 16-19 in Boston, Massachusetts, NewAmsterdam Pharma presented the design of SPINOZA, a new phase 2b trial (NCT07794670)testing whether its CETP inhibitor, obicetrapib, can slow a blood biomarker of AD pathology in adults with preclinical disease.1

The trial builds on a biomarker substudy of the company's completed cardiovascular trial, BROADWAY, in which obicetrapib slowed the rise of that same biomarker, with the effect growing stronger as APOE4 genetic risk increased.

SPINOZA is a multicenter, randomized, double-blind, placebo-controlled trial, led by Michael H. Davidson, MD, and colleagues at NewAmsterdam Pharma, enrolling adults 55 to 85 years old with preclinical AD, a stage at which amyloid and tau biomarkers are present without clinical dementia. Eligible participants carry 1 of 3 APOE genotypes, APOE3/E3, APOE3/E4, or APOE4/E4, and must meet genotype-specific age windows along with plasma p-tau217 thresholds; participants with an APOE3/E4 or APOE3/E3 genotype must also meet a plasma glial fibrillary acidic protein (GFAP) threshold.

After a 6-week screening period, the trial will randomize approximately 400 participants 1:1 to obicetrapib 10 mg or placebo, stratified by genotype, with a minimum of 100 APOE4/E4 homozygotes required. The double-blind treatment period runs 52 weeks, after which participants may enter an optional 26-week open-label extension on obicetrapib, followed by a 4-week safety follow-up. An independent, unblinded statistician will conduct a prespecified interim analysis to support sample-size re-estimation and possible enrichment of the study population, while the sponsor remains blinded.

READ MORE: Spectris Misses Primary End Point in Pivotal HOPE Trial for Alzheimer Disease

The primary endpoint of the study is change from baseline to week 52 in plasma p-tau217, while secondary endpoints include changes in several other plasma AD biomarkers, including amyloid-beta 42/40 and p-tau217 ratios and brain-derived tau, plus change on the Preclinical Alzheimer's Cognitive Composite 5 (PACC5), a cognitive test battery.

Exploratory endpoints cover blood-based markers of astrocytic reactivity, neurodegeneration, neuroinflammation, and synaptic integrity, functional performance measured by the Amsterdam Instrumental Activities of Daily Living scale, and lipid biology markers including LDL, HDL, and triglycerides, alongside standard safety monitoring for treatment-emergent adverse events.1

A cardiovascular trial's unexpected Alzheimer signal

Up to 66% of people with AD carry at least 1 APOE4 allele, the strongest known genetic risk factor for the common, late-onset form of the disease; impaired lipid transport in APOE4 carriers is thought to drive a cycle of oxidative stress, neuroinflammation, and cholesterol buildup that contributes to AD pathology. Plasma p-tau217 has emerged as a reliable biomarker of that pathology, rising exponentially in cognitively unimpaired APOE4 carriers after age 65.

That biomarker became central to obicetrapib's Alzheimer story after NewAmsterdam Pharma first reported that a prespecified biomarker substudy of BROADWAY, a cardiovascular outcomes trial in 2530 people with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia, showed that obicetrapib significantly blunted the 12-month rise in plasma p-tau217 relative to placebo.2

Among the 1535-participant substudy population, p-tau217 rose by 2.09% with obicetrapib versus 4.94% with placebo, a difference of 2.84 percentage points (P =.025); the effect followed an APOE genotype gradient, widening to a 5.74-point difference in APOE4 carriers (P =.022) and a 20.48-point difference in the 29 APOE4 homozygotes, whose p-tau217 levels fell by 7.81% on obicetrapib while rising 12.67% on placebo (P =.010).

The findings, later discussed by BROADWAY investigator Philip Scheltens, MD, PhD, helped support obicetrapib's ongoing European regulatory review for cholesterol-lowering indications and positioned the drug as a candidate for both cardiovascular and neurodegenerative disease. That dual rationale, that CETP inhibition might address upstream lipid dysregulation implicated in amyloid accumulation, tau pathology, astrocytic reactivity, neuroinflammation, and neurodegeneration, provided the basis for testing obicetrapib directly in a dedicated Alzheimer population through SPINOZA.1,3

The authors characterized SPINOZA as evaluating obicetrapib as a novel therapeutic strategy in preclinical AD. By pairing plasma p-tau217 as a primary endpoint with a broader biomarker panel and cognitive and functional assessments, they said the trial is designed to determine whether targeting lipid biology can influence the pathways involved in early AD progression, with results expected to inform the broader clinical development of CETP inhibition as an Alzheimer prevention strategy.1

For more CTAD 2026 coverage, click here.

REFERENCES
1. Davidson MH, Ditmarsch M, Hsieh A, Walker A, Johnson A, Kastelein JJP. SPINOZA: rationale and design of a phase 2b trial of obicetrapib in APOE-stratified preclinical Alzheimer's disease. Presented at: 2026 Clinical Trials on Alzheimer's Disease Conference; November 16-19, 2026; Boston, MA.
2. Davidson MH, Szarek M, Scheltens P, et al. Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. J Prev Alzheimers Dis. 2026;13(1):100394. doi:10.1016/j.tjpad.2025.100394
3. Davidson MH, et al. Am J Prev Cardiol. 2026;26:101442.

Related to this article